San Francisco, USA, 4th October 2016 / Sciad Newswire / Biologist and inventor of new transposase-based tool, Kate Caves discusses DNA2.0’s emerging cell engineering capabilities at SynBioBeta.

DNA2.0 Inc., a pioneer in bioengineering solutions, recently announced the issuance of a genomic modification patent for an innovative transposon- and transposase-based tool that, combined with the company’s industrial scale gene synthesis and machine learning expertise, shows great promise in the development of protein pharmaceuticals. Inventor and DNA2.0 biologist Kate Caves will discuss the rapidly emerging field of genomic engineering at SynBioBeta in San Francisco, in an October 4 panel titled, “Engineered Cell Therapies and Antibodies.”

“Over the past year, DNA2.0 expanded our capabilities with the acquisition of MIGS and its humanization and antibody production capabilities,” said Caves, director of business development and marketing for DNA2.0. “We believe that by combining our new antibody expertise and cell-line engineering tools, we can enable the discovery of protein pharmaceuticals on an integrated, unparalleled platform to accelerate timelines and provide outstanding quality and results for our customers.”

DNA2.0 has 16 patents in the U.S.


About Kate Caves

As Head of Business Development and Marketing, she leads DNA2.0’s sales and marketing activities in building a successful track record for bridging technology and business development strategies to deliver high-quality services and products. Prior to her role as Director of Business Development, Kate built the DNA2.0 mammalian expression facility and lead the research and development of DNA.0’s high-impact Transposase Technology. Kate was a research fellow for the California Institute of Regenerative Medicine where she worked on ground-breaking Stem Cell reprogramming technologies at City of Hope. Kate received her Bachelors of Science from Wellesley College and Masters of Biotechnology at California State University.

About DNA2.0

DNA2.0 is the leading bioengineering solutions provider, offering an integrated pipeline of tools including gene design, optimization and synthesis, expression vectors, and platforms for protein and strain engineering and production. DNA2.0 explores novel applications for synthetic genes and the synergy between efficient gene design and protein optimization technologies. DNA2.0’s tools and solutions are fueling the transformation of biology from a discovery science to an engineering discipline. The company is privately held and is headquartered in Newark, California. For more information, please visit

Got an innovation you need bringing to life?

We’d love to hear from you! Head to our contact page to start a conversation.

Photo of Alex Curtis